NYMOX PHARMACEUTICAL CORP (NYMXF)
Nymox Pharmaceutical Corporation is a biopharmaceutical firm focused on the research and development of medications for the aging population. Operating internationally, including in Canada, the United States, and Europe, the company's flagship drug candidate is Fexapotide Triflutate (NX-1207). This compound is currently undergoing various clinical trials for conditions such as benign prostatic hyperplasia and low-grade localized prostate cancer, with preclinical investigations also underway for hepatocellular carcinoma. Beyond its drug pipeline, Nymox develops and offers two diagnostic products: NicAlert, which identifies tobacco usage, and TobacAlert, designed to detect exposure to secondhand smoke. The company is also actively engaged in developing treatments for Alzheimer's disease. Nymox Pharmaceutical Corporation was established in 1989 and maintains its headquarters in Nassau, the Bahamas.
Sector: In Vitro & In Vivo Diagnostic Substances
Industry: Biotechnology
Nymox Pharmaceutical Corporation
OTC:NYMXFHealthcare · Biotechnology
+96.33%$0.0589
Mkt Cap-
Float56.1M
O/S-
Vol
$ Vol
RVOL
Inst Own-
SI<0.1%
Earnings
Dilution
Financials Summary
Revenue$0
Net Income-$4.28M
Total Assets$576K
Free Cash Flow-$1.81M
Debt & Equity
Total Debt$0
Total Equity-$9.3M
Shares Outstanding
Short Interest
Split History
No splits on record
Nothing in NYMXF's public trading history: no forward or reverse split has affected the share count.
Balance Sheet Details
Assets$576K
Liabilities$9.88M
Accounts Receivable$22K
Accounts Payable$4.08M
Inventory$0
PP&E (Net)$1K
Goodwill$0
Intangible Assets$0
Income Statement
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 |
| Revenue | $0 | $0 | $0 | $0 | $0 | $5K | $116K | $299K | $224K | $284K |
| YoY Growth | - | - | - | - | - | -95.7% | -61.2% | 33.5% | -21.1% | - |
| Cost of Revenue | $1K | $1K | $11K | $12K | $12K | $13K | $67K | $141K | $150K | $176K |
| Gross Profit | -$1K | -$1K | -$11K | -$12K | -$12K | -$8K | $49K | $158K | $74K | $108K |
| Gross Margin | - | - | - | - | - | -160.0% | 42.2% | 52.8% | 33.0% | 38.0% |
| Research and Development | $1.48M | $3.28M | $3.98M | $3.76M | $6.65M | $8.11M | $7.37M | $6.67M | $7.87M | $6.8M |
| Selling, General, and Administrative | $2.19M | $1M | $4.36M | $2.88M | $5.85M | $3.6M | $6.01M | $4.13M | $5.44M | $6.18M |
| Other | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Operating Expenses | $3.68M | $4.28M | $8.34M | $6.64M | $12.49M | $11.71M | $13.37M | $10.8M | $13.31M | $12.98M |
| Operating Income (EBIT) | -$3.68M | -$4.28M | -$8.35M | -$6.65M | -$12.5M | -$11.72M | -$13.32M | -$10.64M | -$13.23M | -$12.87M |
| Operating Margin | - | - | - | - | - | -234400.0% | -11487.1% | -3558.9% | -5908.5% | -4531.7% |
| Interest Expense | $587K | $226K | $61K | $43K | $39K | $42K | $38K | $18K | $204K | $234K |
| Interest Income | $2K | $17K | $6K | $1K | $8K | $27K | $213K | $72K | $11K | $4K |
| Other Income (Expense) | -$598K | -$209K | -$494K | $76K | -$33K | -$18K | $163K | $47K | -$194K | -$240K |
| Income Before Tax (EBT) | -$4.28M | -$4.49M | -$8.84M | -$6.58M | -$12.54M | -$11.74M | -$13.16M | -$10.59M | -$13.43M | -$13.11M |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $0 | $0 | -$2 | -$0 | -$0 |
| Net Income | -$4.28M | -$4.49M | -$8.84M | -$6.58M | -$12.54M | -$11.74M | -$13.16M | -$10.59M | -$13.43M | -$13.11M |
| Net Income Margin | - | - | - | - | - | -234760.0% | -11346.6% | -3543.1% | -5995.1% | -4616.2% |
| Supplementary Data | ||||||||||
| EPS | -0.04 | -0.05 | -0.10 | -0.07 | -0.15 | -0.16 | -0.19 | -0.18 | -0.26 | -0.28 |
| Diluted EPS | -0.04 | -0.05 | -0.10 | -0.07 | -0.15 | -0.16 | -0.19 | -0.18 | -0.26 | -0.28 |
| Weighted Average OS | 96.04M | 93.67M | 91.69M | 89.38M | 81.98M | 73.82M | 68.85M | 60.47M | 52.65M | 46.16M |
| EBITDA | -$3.56M | -$4.26M | -$8.77M | -$6.52M | -$12.49M | -$11.71M | -$13.12M | -$10.57M | -$13.22M | -$12.87M |
| EBITDA Margin | - | - | - | - | - | -234220.0% | -11306.0% | -3536.1% | -5903.6% | -4532.7% |
Balance Sheet
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 |
| Assets | ||||||||||
| Current Assets | ||||||||||
| Cash and Cash Equivalents | $6K | $74K | $70K | $1.4M | $830K | $3.61M | $5.24M | $7.95M | $851K | $2.02M |
| Short-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cash and Short-Term Investments | $6K | $74K | $70K | $1.4M | $830K | $3.61M | $5.24M | $7.95M | $851K | $2.02M |
| Accounts Receivable | $22K | $27K | $11K | $10K | $13K | $20K | $18K | $14K | $87K | $9K |
| Inventory | $0 | $0 | $0 | $0 | $34K | $34K | $23K | $41K | $15K | $3K |
| Other Current Assets | $0 | $0 | $0 | $0 | $132K | $200K | $20K | $23K | $1K | $7K |
| Total Current Assets | $575K | $653K | $625K | $1.46M | $1.04M | $3.89M | $5.33M | $8.03M | $961K | $2.04M |
| Long-Term Assets | ||||||||||
| Property, Plant & Equipment Net | $1K | $1K | $2K | $168K | $406K | $450K | $161K | $33K | $1K | $2K |
| Goodwill | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Intangible Assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $0 | $589K | $589K | $589K | $868K | $718K | $0 |
| Deferred Tax Assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Long-Term Assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $17K | $17K | $17K |
| Total Long-Term Assets | $1K | $1K | $2K | $168K | $995K | $1.04M | $750K | $918K | $736K | $19K |
| Other Assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Assets | $576K | $654K | $627K | $1.63M | $2.03M | $4.93M | $6.08M | $8.94M | $1.7M | $2.06M |
| Liabilities | ||||||||||
| Current Liabilities | ||||||||||
| Accounts Payable | $4.08M | $4.12M | $3.02M | $1.7M | $1.27M | $1.4M | $1.63M | $808K | $2.02M | $1.14M |
| Short-Term Debt | $0 | $0 | $750K | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Current Income Tax Payable | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Current Unearned Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Current Liabilities | $5.11M | $3.29M | $0 | $5K | $23K | $124K | $40K | $50K | $0 | $945K |
| Total Current Liabilities | $9.88M | $7.43M | $3.8M | $2.11M | $1.79M | $1.83M | $2.04M | $1.07M | $2.23M | $1.37M |
| Long-Term Liabilities | ||||||||||
| Long-Term Debt | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $931K |
| Long-Term Unearned Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-Term Deferred Tax Liabilities | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Long-Term Liabilities | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | -$931K |
| Total Long-Term Liabilities | $0 | $0 | $0 | $0 | $163K | $368K | $3K | $0 | $0 | $931K |
| Other Liabilities | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $9.88M | $7.43M | $3.8M | $2.11M | $1.95M | $2.2M | $2.04M | $1.07M | $2.23M | $2.3M |
| Stockholders' Equity | ||||||||||
| Preferred Stock | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Common Stock | $174.16M | $177.69M | $173.82M | $171.67M | $165.06M | $151.72M | $136.55M | $126.68M | $108.2M | $92.13M |
| Retained Earnings | -$216.75M | -$212.47M | -$207.98M | -$199.14M | -$192.56M | -$180.03M | -$168.29M | -$155.11M | -$144.52M | -$131.09M |
| Comprehensive Income & Other | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Stockholders' Equity | $33.29M | $28.01M | $30.99M | $26.98M | $27.58M | $31.04M | $35.77M | $36.3M | $35.79M | $38.72M |
| Total Equity | -$9.3M | -$6.78M | -$3.17M | -$482K | $83K | $2.73M | $4.04M | $7.87M | -$533K | -$242K |
| Minority Interest | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities and Equity | $576K | $654K | $627K | $1.63M | $2.03M | $4.93M | $6.08M | $8.94M | $1.7M | $2.06M |
| Supplementary Data | ||||||||||
| Total Debt | $0 | $0 | $750K | $173K | $391K | $426K | $147K | $0 | $0 | $931K |
| Net Debt | -$6K | -$74K | $680K | -$1.23M | -$439K | -$3.19M | -$5.09M | -$7.95M | -$851K | -$1.09M |
Cash Flow Statement
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 |
| Operating Activities | ||||||||||
| Net Income | -$4.28M | -$4.49M | -$8.84M | -$6.58M | -$12.54M | -$11.74M | -$13.16M | -$10.59M | -$13.43M | -$13.11M |
| Depreciation & Amortization | $126K | $1K | $11K | $12K | $12K | $9K | $9K | $3K | $1K | $3K |
| Deferred Income Tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Stock-Based Compensation | $1.71M | $671K | $3.36M | $593K | $2.6M | $1.75M | $3.01M | $0 | $0 | $0 |
| Changes in Working Capital: | ||||||||||
| Accounts Receivable | $5K | -$16K | -$1K | $3K | $7K | -$1K | -$4K | $73K | -$77K | $269K |
| Inventory | $0 | $0 | $0 | $0 | $0 | -$11K | $17K | -$25K | -$13K | $35K |
| Accounts Payable | $0 | $0 | $0 | $376K | -$165K | -$172K | $819K | -$1.16M | $863K | -$883K |
| Other Working Capital | $630K | $1.24M | $822K | $116K | $18K | -$130K | -$6K | -$17K | $0 | -$7K |
| Total Working Capital Change | $635K | $1.22M | $821K | $495K | -$140K | -$314K | $826K | -$1.13M | $773K | -$586K |
| Other Non-Cash Items | $0 | $671K | $598K | $509K | $3.03M | $2.21M | $4.08M | $5.03M | $5.68M | $9.78M |
| Net Cash from Operating | -$1.81M | -$2.6M | -$4.06M | -$5.21M | -$9.82M | -$10.04M | -$7.43M | -$7.8M | -$6.21M | -$4.5M |
| Investing Activities | ||||||||||
| Capital Expenditures | -$1K | $0 | -$3K | $0 | -$6K | -$13K | $0 | -$36K | $0 | -$2K |
| Acquisitions | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Purchases of Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Sales of Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Investing Activities | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Cash from Investing | -$1K | $0 | -$3K | $0 | -$6K | -$13K | $0 | -$36K | $0 | -$2K |
| Financing Activities | ||||||||||
| Debt Repaid | - | $64K | $173K | $229K | $238K | $265K | $277K | - | - | - |
| Common Stock Issuance | $0 | $0 | $1.15M | $6.01M | $7.28M | $8.69M | $5M | $14.93M | $5.04M | $6.15M |
| Common Stock Repurchases | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Financing Activities | $0 | $0 | -$173K | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Cash from Financing | $1.74M | $2.6M | $2.73M | $5.78M | $7.04M | $8.42M | $4.72M | $14.93M | $5.04M | $6.15M |
| Forex Effect | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Change in Cash | -$68K | $4K | $1.33M | $573K | -$2.78M | -$1.63M | -$2.71M | $7.09M | -$1.17M | $1.64M |
| Supplementary Data | ||||||||||
| Operating Cash Flow | -$1.81M | -$2.6M | -$4.06M | -$5.21M | -$9.82M | -$10.04M | -$7.43M | -$7.8M | -$6.21M | -$4.5M |
| Capital Expenditure | -$1K | $0 | -$3K | $0 | -$6K | -$13K | $0 | -$36K | $0 | -$2K |
| Free Cash Flow | -$1.81M | -$2.6M | -$4.06M | -$5.21M | -$9.83M | -$10.05M | -$7.43M | -$7.84M | -$6.21M | -$4.5M |
| Cash at Beginning | $74K | $70K | -$1.4M | $830K | $3.61M | $5.24M | $7.95M | $851K | $2.02M | $375K |
| Cash at End | $6K | $74K | -$70K | $1.4M | $830K | $3.61M | $5.24M | $7.95M | $851K | $2.02M |